fda shortage list tirzepatide Lilly's weight-loss drug removed from FDA's May 18, 2026: FDA warns

Author contribution: All authors contributed towards writing the initial draft, revising the manuscript and reading the final proof

Understandably, the study findings spread concern and fueled debate in the medical community and beyond

Heymsfield: Im not aware of any specific research other than I do believe that because the interest in this pathway, not just for bimagrumab, but for all these myostatin inhibitors, I think theres a lot of interest and Im absolutely certain that there are labs trying to figure out exactly what the underlying mechanism is

Aumolertinib is a third-generation molecular targeted drug that acts as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic activity

Makers of the selected drugs will have until February 28 to decide if they will participate in the negotiations

Histone-modifying enzymes represent key epigenetic markers